Literature DB >> 2233474

Prevalence of chronic fatigue syndrome in an Australian population.

A R Lloyd1, I Hickie, C R Boughton, O Spencer, D Wakefield.   

Abstract

An epidemiological study was undertaken to provide the first reported estimate of the point prevalence of chronic fatigue syndrome in an Australian community. After a pilot study in a separate location, the population of the Richmond Valley, New South Wales, was sampled using a structured case-finding technique, which included notification from local medical practitioners, the use of a screening questionnaire and standardised interviews conducted by a physician and psychiatrist. In addition, investigations were performed to exclude alternative diagnoses and to assess cell-mediated immunity. Forty-two patients with chronic fatigue syndrome, with a female:male ratio of 1.3:1.0, were detected in a population of 114,000. The mean age at onset of symptoms was 28.6 years (SD, 12.3 years), and the median duration of symptoms from onset to sampling date was 30 months. The social status of the patients was distributed in accordance with that of the remainder of the population sampled, with no bias towards the middle or upper social classes. The disorder was causing considerable incapacity, with 43% of patients unable to attend school or work. The conservative estimate from this study suggests a prevalence on June 30 1988 of 37.1 cases per 100,000 (95% confidence interval [CI], 26.8-50.2). Chronic fatigue syndrome is an important disorder in this Australian community that affects young individuals from all social classes and causes considerable ill health and disability.

Entities:  

Mesh:

Year:  1990        PMID: 2233474     DOI: 10.5694/j.1326-5377.1990.tb126191.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  62 in total

Review 1.  Toward a model of social course in chronic illness: the example of chronic fatigue syndrome.

Authors:  N C Ware
Journal:  Cult Med Psychiatry       Date:  1999-09

2.  Chronic fatigue syndrome: does it need more healthcare resources?

Authors:  A Lloyd; H Pender
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 3.  Chronic fatigue syndrome: the need for subtypes.

Authors:  Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King
Journal:  Neuropsychol Rev       Date:  2005-03       Impact factor: 7.444

4.  The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study.

Authors:  S Wessely; T Chalder; S Hirsch; P Wallace; D Wright
Journal:  Am J Public Health       Date:  1997-09       Impact factor: 9.308

5.  Issues in Estimating Rates of Pediatric Chronic Fatigue Syndrome and Myalgic Encephalomyelitis in a Community-based Sample.

Authors:  Leonard A Jason; Ben Z Katz; Cynthia Mears; Rachel Jantke; Abby Brown; Madison Sunnquist; Kelly O'Connor
Journal:  Avicenna J Neuropsychophysiol       Date:  2015-11-21

6.  Cardiovascular characteristics of chronic fatigue syndrome.

Authors:  Sara Bozzini; Andrea Albergati; Enrica Capelli; Lorenzo Lorusso; Carmine Gazzaruso; Gabriele Pelissero; Colomba Falcone
Journal:  Biomed Rep       Date:  2017-11-28

7.  Chronic fatigue syndrome: have flawed assumptions been derived from treatment-based studies?

Authors:  J A Richman; J A Flaherty; K M Rospenda
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

8.  Differential diagnosis of chronic fatigue syndrome and major depressive disorder.

Authors:  Caroline Hawk; Leonard A Jason; Susan Torres-Harding
Journal:  Int J Behav Med       Date:  2006

9.  A systematic review of chronic fatigue syndrome: don't assume it's depression.

Authors:  James P Griffith; Fahd A Zarrouf
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 10.  Sleep abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a review.

Authors:  Melinda L Jackson; Dorothy Bruck
Journal:  J Clin Sleep Med       Date:  2012-12-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.